GlassScriptPhysician profile
Patricia L Isaacs
NPI 1790916690
$46,865.54
in general payments reported to CMS, 2019-2025
36 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,809 · 2020: $1,430 · 2021: $16K · 2022: $20K · 2023: $4,484 · 2024: $479 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,331 · Food and Beverage: $2,520 · Travel and Lodging: $76.85 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,331.25 |
| Food and Beverage | $2,520.47 |
| Travel and Lodging | $76.85 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,160.32 | 2021-2023 | |
| Novo Nordisk INC | $13,661.61 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,680.62 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $1,222.35 | 2019-2022 | |
| Allergan, INC. | $624.98 | 2019-2021 | |
| Horizon Therapeutics Plc | $579.17 | 2019 | |
| Pfizer INC. | $439.34 | 2019-2025 | |
| Amarin Pharma, INC. | $347.10 | 2019-2022 | |
| Lilly USA, LLC | $316.44 | 2019-2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $294.64 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $293.74 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $284.47 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.03 | 2019-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $243.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $242.51 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $227.96 | 2019-2023 | Freestyle Libre |
| Exact Sciences Corporation | $218.19 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $194.52 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $175.39 | 2022 | |
| Sumitomo Pharma America, INC. | $133.43 | 2023 | Gemtesa |
| Astellas Pharma US INC | $126.72 | 2019-2023 | Veozah |
| Urovant Sciences INC | $124.74 | 2022 | |
| Phathom Pharmaceuticals, INC. | $124.74 | 2024 | Voquezna |
| Radius Health, INC. | $122.55 | 2025 | Tymlos |
| Dexcom, INC. | $119.03 | 2023 | Dexcom G7 Gss (161) |
| Sanofi-Aventis U.S. LLC | $111.15 | 2019 | |
| Merck Sharp & Dohme LLC | $110.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.89 | 2019 | |
| Alkermes, INC. | $99.99 | 2020 | |
| Daiichi Sankyo INC. | $53.19 | 2019 | |
| Tactile Systems Technology INC | $41.03 | 2019 | |
| Janssen Biotech, INC. | $36.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.64 | 2019-2020 | |
| Genentech USA, INC. | $20.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Dynavax Technologies Corporation | $6.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Isaacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.